SCHEMBL1975909

SCHEMBL1975909

CCCn1c(C)c(C(=O)N[C@H](c2cccc(F)c2)C2CCC2)c(C)cc1=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.46
TACR3 P29371 10/20 0.43
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
OPRL1 P41146 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
SMYD3 Q9H7B4 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
SLC6A9 P48067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974336 0.91 CYP2C9 (0.45) CYP2C9TACR3MEN1KMT2ACYP2D6
SCHEMBL10150597 0.90 CYP2C9 (0.44) CYP2C9TACR3MEN1KMT2ACYP2D6
SCHEMBL1977657 0.86 CYP2C9 (0.45) CYP2C9TACR3MEN1KMT2ACYP2D6
SCHEMBL1979946 0.85 CYP2C9 (0.46) CYP2C9TACR3MEN1KMT2ACYP2D6
SCHEMBL1974913 0.85 CYP2C9 (0.46) CYP2C9TACR3MEN1KMT2AOPRL1
SCHEMBL1972226 0.85 CYP2C9 (0.49) CYP2C9TACR3MEN1KMT2ACYP2C19
SCHEMBL11917800 0.84 CYP2C9 (0.47) CYP2C9TACR3MEN1KMT2AOPRL1
SCHEMBL1974496 0.84 CYP2C9 (0.43) CYP2C9TACR3MEN1KMT2AOPRL1
SCHEMBL1975021 0.84 CYP2C9 (0.43) CYP2C9TACR3MEN1KMT2AOPRL1
SCHEMBL1978893 0.84 CYP2C9 (0.45) CYP2C9TACR3MEN1KMT2AOPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
WO-2011072691-A1 PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-06-23 WO disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144164-A1 Pyridone derivatives as NK3 antagonists KCNK3, GRIK3, KCND3 CYP2C9 2501/4885TACR3 26/4885MEN1 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.